Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is expected to issue its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($55.80) per share for the quarter.
Enveric Biosciences Trading Down 2.5%
ENVB opened at $1.96 on Friday. The firm has a market cap of $2.72 million, a price-to-earnings ratio of -0.05 and a beta of 0.31. Enveric Biosciences has a 12 month low of $1.82 and a 12 month high of $21.48. The stock has a fifty day moving average price of $2.74 and a 200-day moving average price of $5.57.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.
Enveric Biosciences Company Profile
Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.
Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.
Further Reading
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
